HLS Therapeutics Announces 8 Years of Data Protection for Vascepa®

About this update from Hls Therapeutics, Inc.

[{"type":"text","content":"\n\n\n\nHLS Therapeutics Announces 8 Years of Data Protection for Vascepa®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO, Jan. 6, 2020\n\n\n\nPeak-year sales estimate increases to CAD$200-300 million, from CAD$150-250 million Commercial launch expected to take place in the mid-February 2020 timeframe Vascepa is the subject of numerous Canadian issued and pending patents with expiration dates which could extend to 2039 TORONTO, Jan. 6, 2020 /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that today Vascepa® was added to Health Canada's Register of Innovative Drugs and as a result it will benefit from data protection for a term of eight years from the date of the issuance of the notice of compliance. All amounts are in United States (\"U.S.\") dollars unless otherwise stated.\n\"We are pleased to announce this development and remain on track for a mid-February 2020 launch for Vascepa. Having taken into consideration all aspects of the granted indication for Vascepa, we now believe that peak year sales for the product in Canada could reach CAD$200-300 million per year, up from our previous estimate of CAD$150-250 million per year,\" said Greg Gubitz, CEO of HLS. \"While the approval of a broad label raises our overall potential, it doesn't change what we need to do over the first 12 months of commercialization which is to lay-down the fundamental basis of the product's benefits with key opinion leaders, and seed the basis of public formulary coverage that should take place within the first 12 to 24 months. In turn, we would expect to reach our peak year sales run-rate approximately 4-5 years following product launch.\"\nPreviously, on December 31, 2019, Health Canada approved the use of Vascepa® (icosapent ethyl) to reduce the risk of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in stati...

More updates from Hls Therapeutics, Inc.